Company / Capital Expenditures
Intellia Therapeutics, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$1.1M
FY2025
5-year range
$1.1M / $14.0M
FY2021-FY2025
Trend
-80.5%
vs FY2024
Sector context
#141 of 145
Health Care
What the data says
Among 145 Health Care companies, Intellia Therapeutics, Inc. is in the bottom 3% for capital expenditures. Capital Expenditures has fluctuated over the past 10 years, ranging from $1M in FY2025 to $14M in FY2023.
Based on SEC 10-K filings.
$1M in FY2025 with a 5-year CAGR of -20.6%.
Declined from $14M to $1M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -56.3%
- 5-Year CAGR
- -20.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 145This company $1.1M Sector average $268.6M
▼
-99.6% below sector average
Key checks
Key Insights
- 5-year CAGR of -20.6%, indicating a declining trend.
- In FY2025, capital expenditures decreased 80.5% year-over-year.
- Ranks #141 out of 145 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.1M | -80.5% |
| FY2024 | $5.8M | -58.7% |
| FY2023 | $14.0M | +3.1% |
| FY2022 | $13.6M | +6.3% |
| FY2021 | $12.8M | +255.8% |
| FY2020 | $3.6M | -47.2% |
| FY2019 | $6.8M | +6.9% |
| FY2018 | $6.4M | -37.0% |
| FY2017 | $10.1M | +63.7% |
| FY2016 | $6.2M | +141.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026